Jump to content

Eldelumab

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 15:16, 28 February 2016 (molar weight unit in g/mol (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Eldelumab
Monoclonal antibody
Type?
SourceHuman
Targetinterferon gamma-induced protein
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6502H10024N1736O2026S48
Molar mass146.5 kg/mol g·mol−1

Eldelumab is a monoclonal antibody designed for the treatment of Crohn's disease and ulcerative colitis.[1]

This drug was developed by Bristol-Myers Squibb.

References

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Eldelumab, American Medical Association.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Eldelumab&oldid=707382908"